Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective

por Zhu, Wentao, Zheng, Miaomiao, Xia, Panpan, Hong, Wanglong, Ma, Guoqiang, Shen, Aizong
Publicado 2023